• Equity Investment: AstraZeneca completed an additional equity investment of $140 million in Cellectis.
• Cash and Cash Equivalents: $264 million as of December 31, 2024, compared to $156 million as of December 31, 2023.
• Revenue from Collaboration: $47 million received from AstraZeneca under the joint research and collaboration agreement.
• Credit Facility Drawdown: EUR 20 million drawn from the European Investment Bank credit facility.
• Cash Runway: Sufficient to fund operations into mid-2027.
• Expenses: $47 million paid to suppliers, $40 million in wages, bonuses, and social expenses, $11 million in lease debt payments, and $5 million repayment of the PGE loan.

• Warning! GuruFocus has detected 6 Warning Signs with CLLS.

Release Date: March 14, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Cellectis SA (NASDAQ:CLLS) announced the start of three new research and development programs in collaboration with AstraZeneca, including allogenic CAR T therapies for hematological malignancies and solid tumors, as well as in vivo gene therapy for genetic disorders.
• AstraZeneca completed an additional equity investment of $140 million in Cellectis SA (NASDAQ:CLLS), increasing its ownership to approximately 44% of the share capital.
• Cellectis SA (NASDAQ:CLLS) secured a EUR40 million credit facility from the European Investment Bank, ensuring a cash runway to fund operations into mid-2027.
• The FDA granted orphan drug designation to Cellectis SA (NASDAQ:CLLS)'s product candidate UCART22 for the treatment of relapsed or refractory acute lymphoblastic leukemia.
• Cellectis SA (NASDAQ:CLLS) showcased promising CAR T strategies utilizing TALEN gene editing technology, with data presented at major conferences and published in scientific journals.

Negative Points

• Cellectis SA (NASDAQ:CLLS) faces risks and uncertainties that may cause actual results to differ from forecasts, as highlighted in their SEC filings.
• The company is still in the early stages of clinical trials, with Phase 1 data for UCART22 and UCART20x22 expected only in late 2025.
• Cellectis SA (NASDAQ:CLLS) has ongoing legal matters, such as the arbitration with Sevier, which could impact future operations.
• The competitive landscape for CAR T therapies is challenging, with recent discontinuations in the field highlighting potential hurdles.
• Cellectis SA (NASDAQ:CLLS) has a significant cash burn, with a net cash burn of $60 million in 2024, despite revenue from partnerships.

Q & A Highlights

Q: Could you provide more details on the upcoming data release for UCART22 in Q3, including patient numbers and data points? A: We plan to have the full Phase 1 dose escalation data set available in Q3. The data release will likely be at an ad hoc event, with additional data shared at the ASH annual conference. More details will be provided as the quarter progresses. (Adrian Kilcoyne, Chief Medical Officer; Arthur Stril, Chief Business Officer)

Q: How is the team setting the internal bar for success for the UCART22 data readout in Q3? A: We are confident in the data seen thus far, considering the heavily pre-treated patient group. We believe the data will meet regulatory requirements, but ongoing interactions with the FDA and EMA will provide further clarity. (Adrian Kilcoyne, Chief Medical Officer)

Q: Can you provide updates on the AstraZeneca collaboration and any near-term milestones? A: The collaboration with AstraZeneca is progressing well, with active discussions and workstreams. We are exploring a wide range of therapeutic areas, including solid tumors and in vivo gene therapy. Specific targets are under wraps, but we aim to disclose comprehensive data sets this year. (Arthur Stril, Chief Business Officer)

Q: What are the potential late-stage development strategies for UCART22, and how might the data inform these decisions? A: We are planning interactions with the FDA and EMA to align on a registration path. While we can't share specifics publicly yet, we believe there is a clear registration path, and the Q3 data release will provide more granularity. (Adrian Kilcoyne, Chief Medical Officer)

Q: How does the recent discontinuation of a competitor's CD22-targeted asset impact your UCART20x22 program? A: The discontinuation highlights the unmet need for non-CD19 CAR T therapies. We believe CD22 is an important target, and our strategy aims to improve durability and address the commercial opportunity. (Arthur Stril, Chief Business Officer; Adrian Kilcoyne, Chief Medical Officer)

For the complete transcript of the earnings call, please refer to the full earnings call transcript.